age1 — Full Portfolio

Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.

BiotechDeep TechHealthtechCambridge, US

NBNessan Bermingham(Executive Officer, Director)inJennifer Doudna(Co-founder)JRJose Rivera(Executive Officer)inJLJohn Leonard(President and Chief Executive Officer)inJBJames Basta(Executive Vice President, General Counsel and Corporate Secretary)inEDEdward Dulac(Executive Vice President, Chief Financial Officer)in

Co-investorsATAtlas VentureAVAvoro Capital AdvisorsECEcoR1 CapitalFOForesite CapitalFIFidelity InvestmentsOROrbiMed

Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).

BiotechDeep TechHealthtechDurham, US

DJDEREK JANTZ(Executive Officer, Director)inMKMATTHEW KANE(Executive Officer, Director)JSJeff Smith(Co-founder)inDJDerek Jantz(Co-founder)inTODD MELBY(Executive Officer)inMAMichael Amoroso(President, Chief Executive Officer)in

Co-investorsAGAgent CapitalALAliment CapitalBRBrace PharmaF-F-Prime CapitalOCOCV PartnersOUOUP (Osage University Partners)+4 more

Autonomy Bio is a biotech company developing drugs targeting human aging to extend healthy lifespan.

BiotechLongevitySan Francisco, US

Co-investorsVAValhalla VenturesKLKleiner PerkinsSOSoftBank Group

Aerska develops RNA interference (RNAi) medicines designed for targeted delivery across the blood-brain barrier to treat, delay, and prevent central nervous system and neurological diseases.

BiotechDeep TechHealthtechMedical Devices

SMStuart Milstein(Co-Founder)inJOJack O’Meara(Cofounder)in

Co-investorsBLBlueYard CapitalENEntrepreneur FirstIAIaso VenturesPSPsyMed VenturesUNUnruly CapitalADAda Ventures+3 more

Aperture Therapeutics uses machine learning to mine genomic and clinical datasets for naturally occurring protective gene variants, then designs oligonucleotide therapeutics that mimic those variants to treat neurodegenerative diseases such as ALS and FTD and delay brain aging.

AI & Machine LearningBiotechLongevity

MJMartin Jacko(Founder & CEO)in

Co-investorsXEXEIA Venture Partners

Arda develops therapeutics using single-cell computational biology to target and eliminate pathogenic cells in chronic diseases.

AI & Machine LearningBiotechMedical DevicesAustin, US

AFAdam Freund(Founder & Chief Executive Officer)inRLRemi-Martin Laberge(Founder and Chief Technology Officer)in

BoardVAVineeta Agarwala(Director)in

Co-investorsANAndreessen HorowitzSTStrawberry Creek VenturesALAlumni VenturesGAGaingelsGVGV (Google Ventures)INIndicator Ventures+3 more

Conception develops stem cell technology to create functional reproductive cells in the laboratory, enabling in-vitro gametogenesis as a solution for individuals facing biological and medical fertility barriers.

BiotechDeep TechHealthtechBerkeley, US

MKMatt Krisiloff(CEO)inBSBianka Seres(President)in

Co-investorsCOCompoundHOHOF CapitalMEMetaplanetSCSciFoundersVUVU Venture Partners

Regeneron is a biopharmaceutical company that discovers, develops, and commercializes medicines using proprietary technologies and genetic databases.

BiotechHealthtechMedical DevicesTarrytown, US

Len Schleifer(Co-Founder)George Yancopoulos(Co-Founder)in

Deciduous Therapeutics develops small molecule and immunomodulatory therapies targeting senescent cells to treat age-related diseases including Type 1 diabetes, autoimmunity, and metabolic disorders.

BiotechDigital HealthLongevitySan Francisco, US

RMRobin Mansukhani(CEO and Co-Founder)inABAnil Bhushan(Scientific Founder)in

BoardDMDylan Morris(Director)in

Co-investorsBOBold Capital PartnersCOCornucopian Capital ManagementCRCRV (Charles River Ventures)OWOwl CapitalQUquadraScope Venture FundAXAxial VC+1 more

Fauna Bio applies AI and computational analysis to its proprietary biobank of data from extreme mammals such as hibernating species to identify drug targets that are conserved across species including humans.

AI & Machine LearningBiotechDeep TechHealthtechEmeryville, US

LGLinda Goodman(Founder)inAshley(CEO)

Co-investorsFAFarvatn VentureGRGRIDS CapitalLILifeforce CapitalMEMetaplanetVIVibe CapitalBEBeagle Ventures+3 more

General Control is developing programmable, multiplexed epigenetic editing therapies designed to control the expression of several genes at once.

BiotechDeep TechLongevity

LNLada Nuzhna(CEO & Founder)in

Co-investorsANAngel Collective Opportunity FundGOGoAhead VenturesMOMoth FundSTStreamlined Ventures

General Proximity develops proximity-based technologies for drug discovery and development.

AI & Machine LearningBiotechDeep TechHealthtechSan Francisco, US

ACArmand Cognetta(Founder)in

Co-investorsY Y CombinatorFEFelicis VenturesMOModi Ventures

Gordian Biotechnology develops therapies aimed at treating age-related diseases to extend healthy lifespan.

AI & Machine LearningBiotechHealthtechLongevity

Co-investorsFIFifty YearsMEMetaplanetPRPrime Movers LabSTStreamlined VenturesW W ventures1010x Founders

A venture capital firm focused on the longevity sector, backing founder-driven companies working on extending human healthy lifespan.

BiotechLongevity

LDLaura Deming(Founder)inACAlex Colville(General Partner)in

Co-investors151517

Loyal develops longevity drugs for dogs, targeting the biological processes of aging to extend healthy lifespan and reduce age-associated disease.

BiotechHealthtechLongevity

CHCeline Halioua(Founder & CEO)in

Co-investorsCOCollaborative FundFIFirst Round CapitalFLFlucas VenturesINInvariantes FundKHKhosla VenturesMEMetaplanet+10 more

San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.

BiotechSan Diego, US

Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)

BoardKBKristina Burow(Director)inRHRichard Heyman(Director)inANAmir Nashat(Director)in

Co-investorsECEcoR1 CapitalLALAVLILilly Asia VenturesNENew Enterprise Associates (NEA)VIVivo CapitalARARCH Venture Partners+2 more

BiotechCambridge, US

Rick Lundberg(Executive Officer)GPGeorge P. Vlasuk(Executive Officer, Director)in

BoardJFJean-Francois Formela(Director)inACAlan Crane(Director)MNMarian Nakada(Director)inBGBrian Gallagher(Director)in

Co-investorsBRBrace PharmaSASanofi VenturesATAtlas VenturePOPolaris PartnersSRSR One Capital Management

NewLimit develops epigenetic reprogramming medicines to extend healthspan and treat age-related diseases at the intersection of computer science and biotechnology.

AI & Machine LearningBiotechLongevitySouth San Francisco, US

BABrian Armstrong(Co-founder, Board of Directors)inBBBlake Byers(Director)inJKJacob Kimmel(Director)inMichael Polansky(Executive Officer)

BoardZDZavain Dar(Director)in

Co-investorsS3S32VAValor Equity Partners8V8VCABAbstract VenturesBEBeyond CapitalDRDraper Associates+8 more

Reservoir Neuroscience is developing therapeutics aimed at repairing the blood-brain barrier.

BiotechHealthtechSan Francisco, US

Aaron Friedman(Executive Officer)Vladimir Senatorov(Director)

BoardTSTracy Saxton(Director)James Summers(Director)Brian Slingerland(Director)

Co-investorsDODolby Family Ventures

Science Corporation develops brain-computer interface and neural engineering technology to restore vision, cognition, and mobility to patients with debilitating conditions.

AI & Machine LearningBiotechDeep TechDigital HealthMedical DevicesAlameda, US

Max Hodak(Chief Executive Officer)

Co-investorsARArtis VenturesAVAvalanche VCBEBeyond CapitalCOConversion CapitalDUDuke Capital PartnersFIFifty Years+8 more

Skeletalis is developing OASIS, a targeted small-molecule platform for musculoskeletal and bone health that concentrates therapy at sites of active bone loss while preserving the body's natural bone remodeling.

BiotechDeep TechHealthtech

Co-investorsPIPillar VCKDKdT Ventures

Unity Biotechnology was a biotechnology company that is no longer operating.

BiotechBrisbane, US

NENathaniel E. David(Executive Officer, Director)inDMDan Marquess(Executive Officer)inKLKeith Leonard(Executive Officer, Director)inTamara Tompkins(Executive Officer)inBob Goeltz(Executive Officer)inJamie Dananberg(Executive Officer)in

Co-investorsARARCH Venture PartnersCYCycad Group LLCECEcoR1 CapitalKHKhosla VenturesVEVenrock

The company builds technology focused on improving patient outcomes in healthcare.

BiotechDeep TechMedical Devices

Co-investorsLULux CapitalFIField VenturesFOFounders Fund